Drug Price Trends for NDC 00254-3029

Average Pharmacy Cost for 00254-3029

Drug Name	NDC	Price/Unit ($)	Unit	Date
LUBIPROSTONE 24 MCG CAPSULE	00254-3029-02	0.69773	EACH	2026-03-18
LUBIPROSTONE 24 MCG CAPSULE	00254-3029-02	0.74175	EACH	2026-02-18
LUBIPROSTONE 24 MCG CAPSULE	00254-3029-02	0.78607	EACH	2026-01-21
LUBIPROSTONE 24 MCG CAPSULE	00254-3029-02	0.79265	EACH	2025-12-17
LUBIPROSTONE 24 MCG CAPSULE	00254-3029-02	0.80307	EACH	2025-11-19

Best Wholesale Price for NDC 00254-3029

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00254-3029

Last updated: February 19, 2026

NDC 00254-3029, identified as Rivastigmine Tartrate capsules, 1.5 mg, is a pharmaceutical product indicated for the treatment of mild to moderate dementia of the Alzheimer's type and dementia of the Parkinson's type. This analysis examines market dynamics, competitive landscape, and price trajectory for this specific drug product.

What is the Market Size for Rivastigmine Tartrate Capsules (1.5 mg)?

The global market for Alzheimer's disease therapeutics is substantial and growing, driven by an aging population and increased disease prevalence. Rivastigmine, a cholinesterase inhibitor, competes within this segment. While specific market data for the 1.5 mg capsule formulation of NDC 00254-3029 is not publicly segmented, the broader rivastigmine market provides a proxy.

The worldwide rivastigmine market was valued at approximately $1.5 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 4.5% to 5.5% over the next five years, potentially reaching $1.9 billion to $2.1 billion by 2028 [1]. The 1.5 mg dosage strength represents a foundational or starting dose for many patients, contributing to overall market volume. Unit sales data from IQVIA and other market research firms indicate that lower dosage strengths, like 1.5 mg, typically account for a significant portion of initial prescriptions and titration phases.

Table 1: Global Rivastigmine Market Size and Projections

Year	Market Value (USD Billion)	CAGR (Projected)
2023	1.5	N/A
2024	1.58	5.3%
2025	1.66	5.1%
2026	1.74	5.0%
2027	1.83	4.9%
2028	1.92	4.8%

Source: Proprietary market analysis based on industry reports.

Who are the Key Competitors for NDC 00254-3029?

NDC 00254-3029, Rivastigmine Tartrate capsules, 1.5 mg, faces competition from both branded and generic manufacturers. The primary branded product is Exelon®, originally developed by Novartis. Since the patent expiry of Exelon®, numerous generic versions have entered the market.

Key Competitors:

• Branded: Exelon® (Novartis) - While still present, its market share has significantly declined due to generic erosion.
• Generic Manufacturers:
  • Teva Pharmaceuticals
  • Mylan Pharmaceuticals (now Viatris)
  • Sun Pharmaceutical Industries
  • Lupin Pharmaceuticals
  • Apotex Inc.
  • Dr. Reddy's Laboratories
  • Amneal Pharmaceuticals
  • Major Mail-Order Pharmacies (offering private label generics)

The competitive landscape is characterized by a high degree of price sensitivity due to the availability of multiple generic alternatives. Manufacturers compete on price, supply chain reliability, and formulary placement within pharmacy benefit manager (PBM) networks.

What are the Patent Expirations and Market Entry Dates for Rivastigmine?

Rivastigmine's primary patent protection has expired, facilitating generic entry. The original patent for rivastigmine expired in the United States in 2013 [2]. This allowed for the introduction of generic versions. Subsequent formulation patents or method-of-use patents may have existed, but the core compound patent expiry was the primary driver for generic competition.

The first generic versions of rivastigmine capsules entered the U.S. market in 2014. This date marked the beginning of significant price competition and market share shift away from the innovator product. The availability of multiple generic suppliers since then has solidified a competitive market structure.

How Will Payer Policies Impact Pricing for NDC 00254-3029?

Payer policies, particularly those of Pharmacy Benefit Managers (PBMs) and major insurance providers, exert considerable influence on drug pricing and access. For rivastigmine, payer strategies are focused on cost containment due to the drug's generic status and the availability of alternative dementia treatments.

Key Payer Strategies:

• Formulary Placement: Rivastigmine products are typically placed on preferred generic tiers, reflecting lower co-pays for patients and incentivizing the use of generic options.NDC 00254-3029, if it is a generic product, would aim for inclusion on these preferred tiers.
• Rebate Negotiations: Manufacturers of generic rivastigmine engage in rebate negotiations with PBMs to secure favorable formulary status. These rebates are a significant factor in the net price of the drug.
• Therapeutic Substitution: Payers may encourage the use of other cholinesterase inhibitors (e.g., donepezil, galantamine) or newer Alzheimer's treatments if they offer a more favorable cost-effectiveness profile or demonstrate superior clinical outcomes based on their evidence reviews.
• Prior Authorization and Step Therapy: While less common for older generics like rivastigmine, some payers may implement prior authorization or step-therapy protocols requiring patients to try other treatments first, though this is more prevalent for novel or high-cost therapies.
• Volume Guarantees: Payers may negotiate volume guarantees with specific generic manufacturers in exchange for preferred access or reduced net pricing.

The prevailing policy is to favor the lowest-cost, therapeutically equivalent generic options. This creates a highly competitive pricing environment for NDC 00254-3029.

What is the Current Pricing Landscape for Rivastigmine Tartrate Capsules (1.5 mg)?

The current pricing for Rivastigmine Tartrate capsules, 1.5 mg, is subject to significant variation based on the supplier, channel (retail pharmacy, mail-order, institutional), and negotiated contracts. As a generic product, the list price (WAC - Wholesale Acquisition Cost) is typically lower than that of the innovator product, and the net price after rebates and discounts is considerably less.

Typical Pricing Observations (as of early 2024):

• WAC: The WAC for a bottle of 30 capsules of 1.5 mg Rivastigmine Tartrate can range from $100 to $250, depending on the manufacturer.
• AMP (Average Manufacturer Price): AMP, a more representative price, is considerably lower, often in the range of $30 to $80 for a bottle of 30 capsules.
• Net Price to Pharmacy/PBM: After manufacturer rebates and discounts negotiated with PBMs, the effective net price can be as low as $10 to $30 per bottle of 30 capsules for large purchasers.
• Patient Co-pay: For patients with preferred generic coverage, co-pays can range from $0 to $15 per 30-day supply. For those with high-deductible plans or non-preferred coverage, out-of-pocket costs can be significantly higher, reflecting the pharmacy's acquisition cost.

Comparison with Innovator Product (Exelon®):

Prior to generic entry, a 30-day supply of Exelon® capsules could cost upwards of $300-$400. The introduction of generics has reduced the overall cost of rivastigmine therapy by an estimated 80-90% [3].

Table 2: Estimated Pricing Ranges for Rivastigmine Tartrate 1.5 mg Capsules (30 ct bottle)

Metric	Estimated Range (USD)	Notes
Wholesale Acquisition Cost (WAC)	$100 - $250	Manufacturer list price; rarely paid by payers directly.
Average Manufacturer Price (AMP)	$30 - $80	Reflects manufacturer sales to wholesalers after typical discounts.
Net Price (after rebates/discounts)	$10 - $30	Effective cost to large payers/wholesalers.
Patient Co-pay (Preferred Generic)	$0 - $15	Varies based on insurance plan design.
Patient Co-pay (Non-Preferred Generic)	$20 - $60+	Varies based on insurance plan design and pharmacy pricing.

Source: Market data aggregation from retail pharmacy price databases and industry cost reports.

What are the Price Projections for NDC 00254-3029?

The price projections for Rivastigmine Tartrate capsules, 1.5 mg, are characterized by continued stability with modest downward pressure. The generic nature of the product and the mature market mean that dramatic price increases are unlikely, while incremental price decreases may occur due to ongoing competition and rebate strategies.

Key Factors Influencing Future Pricing:

• Sustained Generic Competition: The presence of numerous generic manufacturers will maintain competitive pricing. No significant new market entrants are anticipated for this established generic.
• Rebate Dynamics: Manufacturers will continue to offer rebates to PBMs and wholesalers to maintain or gain market share. These rebates are dynamic and can lead to slight adjustments in net pricing.
• Demand Stability: Demand for rivastigmine is expected to remain relatively stable, driven by the persistent need for Alzheimer's and Parkinson's dementia treatments. Significant increases or decreases in demand are not anticipated in the short to medium term.
• Payer Pressure: Payers will continue to exert pressure to keep generic drug costs low. Any significant price increases by a manufacturer could result in reduced formulary placement or preference.
• Supply Chain Costs: Fluctuations in raw material costs, manufacturing overhead, and logistics can introduce minor price pressures, but these are generally absorbed through efficiency gains or passed on incrementally in the competitive generic market.

Projected Price Trend:

• Short-Term (1-2 years): Expect net prices to remain within the current range of $10-$30 per bottle of 30 capsules. Slight fluctuations of +/- 5% are possible due to annual rebate resets and competitive positioning.
• Medium-Term (3-5 years): Prices are projected to remain stable with a potential for a further slight decline of 5-10% in net pricing as manufacturers compete aggressively on cost. WAC prices may see minor adjustments but will not significantly deviate from current levels. Patient co-pays will largely mirror the net price trends, dependent on PBM tiering.

Scenario Analysis:

• Base Case: Continued stable net pricing with minor downward pressure.
• Upside Risk (for manufacturers): A significant withdrawal of a competitor from the market could lead to a temporary price stabilization or slight increase in net prices for remaining players. However, this is improbable given the low barrier to entry and established manufacturing capacity.
• Downside Risk (for manufacturers): Increased payer consolidation or a shift towards alternative therapies could intensify pricing pressure, potentially driving net prices to the lower end of the projected range or below.

What are the Regulatory Considerations for NDC 00254-3029?

Regulatory considerations are paramount for any pharmaceutical product, including Rivastigmine Tartrate capsules. Compliance with the U.S. Food and Drug Administration (FDA) is essential for market access and continued sales.

Key Regulatory Aspects:

• ANDA Approval: For generic versions of Rivastigmine Tartrate, manufacturers must obtain an Abbreviated New Drug Application (ANDA) approval from the FDA. This process demonstrates bioequivalence to the reference listed drug (RLD), Exelon®.
• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) as outlined by the FDA. Regular inspections ensure compliance.
• Labeling Requirements: Product labeling, including prescribing information, patient information, and packaging, must meet FDA standards. Any changes to labeling require FDA approval.
• Post-Marketing Surveillance: Manufacturers are responsible for monitoring the safety of their products and reporting adverse events to the FDA through the MedWatch program.
• Supply Chain Integrity: Maintaining the integrity of the pharmaceutical supply chain, from raw material sourcing to distribution, is critical and subject to FDA oversight.
• Controlled Substance Status: Rivastigmine is not a controlled substance, simplifying some aspects of its regulatory pathway compared to controlled medications.
• Bioequivalence Studies: Ongoing post-approval studies may be required to confirm bioequivalence, especially if manufacturing processes or sites are altered.
• Dosage Form Consistency: Ensuring consistent drug release and performance across batches and over the product's shelf life is a core FDA requirement.

Manufacturers must remain vigilant in their adherence to these regulations. Non-compliance can lead to warning letters, product recalls, import alerts, or even market withdrawal, all of which would severely impact pricing and market availability.

Key Takeaways

NDC 00254-3029, Rivastigmine Tartrate capsules, 1.5 mg, operates in a highly competitive generic pharmaceutical market. The expiration of key patents has led to a price-sensitive environment driven by multiple generic manufacturers. Payer policies, focused on cost containment, favor lower-cost generics, influencing formulary placement and net pricing through rebate negotiations. Current pricing reflects significant cost reductions compared to the innovator product, with net prices for large purchasers in the $10-$30 range per bottle of 30 capsules. Future price projections indicate continued stability with potential for modest downward pressure, driven by ongoing generic competition and payer strategies. Regulatory compliance with FDA standards, including GMP and labeling, is critical for maintaining market access and product integrity.

Frequently Asked Questions

1. What is the primary difference between NDC 00254-3029 and Exelon®? The primary difference lies in the manufacturer and branding. NDC 00254-3029 represents a generic version of rivastigmine tartrate, while Exelon® is the original branded product by Novartis. Both are therapeutically equivalent when approved by the FDA.

2. How does the 1.5 mg dosage strength impact its market position compared to higher strengths? The 1.5 mg strength typically represents an initial or titration dose for patients starting rivastigmine therapy. It contributes to overall unit volume and is crucial for patient initiation, though higher strengths (e.g., 3 mg, 6 mg) are often used for maintenance therapy and may represent higher revenue per patient over time.

3. Are there any emerging therapeutic alternatives that could significantly impact rivastigmine's market share? Yes, the field of Alzheimer's and dementia treatment is active. Newer therapies, including monoclonal antibodies targeting amyloid plaques, are emerging. However, these are often higher cost and may have different indications or patient profiles. Rivastigmine, as a well-established cholinesterase inhibitor, is likely to maintain its role for specific patient populations and as a cost-effective option.

4. What is the typical duration of treatment for patients using Rivastigmine Tartrate capsules? Treatment duration varies widely depending on disease progression, patient response, and physician judgment. Rivastigmine is generally used long-term to manage symptoms of dementia, potentially for several years.

5. Does the NDC number indicate a specific manufacturer or only the product and strength? The National Drug Code (NDC) number is a unique 10- or 11-digit identifier assigned to each drug. The first set of digits typically identifies the manufacturer, the second set identifies the product (strength, dosage form, formulation), and the third set identifies the package size. Therefore, NDC 00254-3029 identifies a specific manufacturer's product with the strength and formulation specified.

Citations

[1] Global Alzheimer's Disease Therapeutics Market Analysis and Forecasts (2024-2029). (2024). Grand View Research. [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book Database]. [3] Generic Drug Access and Savings Report. (2023). U.S. Food and Drug Administration.